Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Forest’s Namenda To Get Label Update After Pediatric Program Failure

This article was originally published in The Pink Sheet Daily

Executive Summary

But Alzheimer’s indication for Namenda and extended-release version will get six months of pediatric exclusivity with a pending NDA for a combo-treatment eligible for the same perks.

You may also be interested in...



Forest Takes Over Namenda Lifecycle-Management Project In Deal With Adamas

Forest will develop and commercialize a once-daily, fixed-dose combination of its own extended-release memantine with donepezil (Pfizer’s Aricept) in the U.S. under a licensing deal with Adamas, which started the project and will retain EU rights to the memantine/donepezil combo.

Beyond mRNA: FDA’s Marks Calls For Platform Agnostic Search For Better COVID Vaccines

Marks opines on what sponsors would need to do to bring a ‘better’ vaccine to market in a NEJM interview. Meanwhile, CDC releases real world data on estimated bivalent booster efficacy.

Departing Words: Merck’s Ken Frazier Cautions Against Profit Maximization

Pharma CEOs must balance optimizing access and profitability, former Merck CEO and soon-to-be ex executive chairman of the company said. Frazier says health care industry must come to table and admit the “system ain’t working,” talks about the need to protect democracy, in a sweeping interview at the STAT Summit.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS077338

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel